1. Reynolds LA, Closson RG. Extemporaneous ophthalmic preparations. Am J Ophthalmol. 1994;117(2):277.
2. Trissel LA. Trissel’s stability of compounded formulations. 4th ed. Washington DC: American Pharmacists Association; 2009. p. 26–7.
3. Doctor PP, Bhat PV, Foster CS. Subconjunctival bevacizumab for corneal neovascularization. Cornea. 2008;27(9):992–5.
4. Genentech. Avastin. Summary of product characteristics. (2010). Available at
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf
. Accessed Jul 2012.
5. Novartis. Lucentis summary of product characteristics. (2012). Available at
https://www.medicines.org.uk/emc/history/19409/SPC/Lucentis+10+mg+ml+solution+for+injection
. Accessed Jul 2012.